9/14/2018 - 12:03 PM EST - Theratechnologies Inc. : Announced that the European Medicines Agency (“EMA”) has confirmed the validity of the marketing authorization application for Trogarzo (ibalizumab) filed on August 28. The validation confirms the submission is complete, and begins the EMA’s centralized review process. As a result, the start of procedure date has been set to September 13. Theratechnologies Inc.
shares T.TH are trading up $0.26 at $9.20.
